Amine functional polyamides
AssigneeGenzyme Corporation
InventorsPradeep DHAL, Kanwen Yang, Robert J. Miller, S. Randall Holmes-Farley
Life of this patent
Estimating the term…
Abstract
Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.
Claims101
A compound comprising the structure of Formula (I):
- wherein:
- i) m is 0, 1, 2, or 3;
- ii) n is 0, 1, 2, or 3;
- iii) o is 0, 1, 2, or 3;
- iv) p is 0 or 1;
- v) r is 0 or 1;
- vi) q is an integer from 1 to 400;
- vii) Qx is NH, (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl;
- viii) Qy is NH—Rw, NH—CH2—Rw, (C1-C10)alkyl, or (C6-C14)aryl,
- wherein Rw is absent or a (C1-C10)alkyl, (C2-C9)heteroalkyl, (C6-C14)aryl, or (C2-C9)heteroaryl;
- ix) Rx and Ry are each independently a pharmaceutically acceptable end group.
A compound comprising the structure of Formula (II):
- wherein:
- i) m is 0, 1, 2, or 3;
- ii) n is 0, 1, 2, or 3;
- iii) o is 0, 1, 2, or 3;
- iv) p is 0 or 1;
- v) r is 0 or 1;
- vi) q is an integer from 1 to 400;
- vii) Qx is NH, (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl;
- viii) Qy is NH—Rw, NH—CH2—Rw, (C1-C10)alkyl, or (C6-C14)aryl,
- wherein Rw is absent or a (C1-C10)alkyl, (C2-C9)heteroalkyl, (C6-C14)aryl, or (C2-C9)heteroaryl;
- ix) Rx and Ry are each independently a pharmaceutically acceptable end group;
- x) X− is each independently a halo or any pharmaceutically acceptable anion;
- xi) Y1 and Y2 are each independently H or (C1-C10)alkyl optionally substituted by one or more substituents selected from the group consisting of (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl, (C1-C10)alkylamine, —S—O—(C1-C10)alkyl, —O(O)C—(C1-C10)alkyl, —(C1-C10)alkyl-COOH, (C3-C10)cycloalkyl-COOH, —(O)CH3, —OH, amide, a dihydroxy group, represented by Formula (D),
- wherein d is an integer from 0 to 25, or
- a polyethylene glycol group, represented by Formula (E)
- wherein e is an integer from 1 to 25.
A compound comprising the structure of Formula (III):
- wherein:
- i) m is 0, 1, 2, or 3;
- ii) n is 0, 1, 2, or 3;
- iii) o is 0, 1, 2, or 3;
- iv) p is 0 or 1;
- v) r is 0 or 1;
- vi) q is an integer from 1 to 400;
- vii) Qx is NH, (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl;
- viii) Qy is NH—Rw, NH—CH2—Rw, (C1-C10)alkyl, or (C6-C14)aryl,
- wherein Rw is absent or a (C1-C10)alkyl, (C2-C9)heteroalkyl, (C6-C14)aryl, or (C2-C9)heteroaryl;
- i) Rx and Ry are each independently a pharmaceutically acceptable end group;
- ix) X− is a halo or any pharmaceutically acceptable anion;
- x) Y1 is H or (C1-C10)alkyl optionally substituted by one or more substituents selected from the group consisting of (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl, (C1-C10)alkylamine, —S—O—(C1-C10)alkyl, —O(O)C—(C1-C10)alkyl, —(C1-C10)alkyl-COOH, (C3-C10)cycloalkyl-COOH, —(O)CH3, —OH, amide, a dihydroxy group, represented by Formula (D),
- wherein d is an integer from 0 to 25, or
- a polyethylene glycol group, represented by Formula (E),
- wherein e is an integer from 1 to 400.
-82. (canceled)
-92. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-157. (canceled)
Dependencies are inferred from the claim text.